Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Comment

Bernard Zinman et al. N Engl J Med. 2016.

. 2016 Mar 17;374(11):1094.

doi: 10.1056/NEJMc1600827.

No abstract available

Comment on

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Clinical Trial.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Sarafidis PA, Tsapas A. Sarafidis PA, et al. N Engl J Med. 2016 Mar 17;374(11):1092. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981941 No abstract available.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Fischereder M, Schönermarck U. Fischereder M, et al. N Engl J Med. 2016 Mar 17;374(11):1092-3. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981942 No abstract available.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Edwards JL. Edwards JL. N Engl J Med. 2016 Mar 17;374(11):1093. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981943 No abstract available.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Rosenstein R, Hough A. Rosenstein R, et al. N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981944 No abstract available.